Repository corticotropin injection versus corticosteroids for protection against renal damage in a focal segmental glomerulosclerosis rodent model
Open Access
- 15 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Nephrology
- Vol. 21 (1), 1-14
- https://doi.org/10.1186/s12882-020-01879-6
Abstract
BackgroundFocal segmental glomerulosclerosis (FSGS) causes renal fibrosis and may lead to kidney failure. FSGS and its common complication, proteinuria, are challenging to treat. Corticosteroids are ineffective in many patients with FSGS, and alternative treatments often yield suboptimal responses. Repository corticotropin injection (RCI; Acthar (R) Gel), a naturally sourced complex mixture of purified adrenocorticotropic hormone analogs and other pituitary peptides, may have beneficial effects on idiopathic FSGS via melanocortin receptor activation.MethodsTwo studies in a preclinical (female Sprague-Dawley rats) puromycin aminonucleoside FSGS model assessed the effect of RCI on renal function and morphology: an 8-week comparison of a single RCI dose with methylprednisolone (N=27), and a 12-week chronic RCI dose range study (N=34). Primary outcomes were proteinuria and renal pathology improvements for measures of renal fibrosis, tubular damage, glomerular injury, and total kidney injury score. Impact of RCI treatment was also determined by assessing urinary biomarkers for renal injury, podocyte expression of podoplanin (a biomarker for injury), podocyte effacement by electron microscopy, and histological staining for fibrosis biomarkers.ResultsCompared with saline treatment, RCI 30IU/kg significantly reduced proteinuria, with a 38% reduction in peak mean urine protein levels on day 28 in the 8-week model, and RCI 10IU/kg, 30IU/kg, and 60IU/kg reduced peak mean urine protein in the 12-week model by 18, 47, and 44%, respectively. RCI also showed significant dose-dependent improvements in fibrosis, interstitial inflammation, tubular injury, and glomerular changes. Total kidney injury score (calculated from histopathological evaluations) demonstrated statistically significant improvements with RCI 30IU/kg in the 8-week study and RCI 60IU/kg in the 12-week study. RCI treatment improved levels of urinary biomarkers of kidney injury (KIM-1 and OPN), expression of podoplanin, and podocyte morphology. RCI also reduced levels of desmin and fibrosis-associated collagen deposition staining. Methylprednisolone did not improve renal function or pathology in this model.ConclusionsThese results provide evidence supporting the improvement of FSGS with RCI, which was superior to corticosteroid treatment in this experimental model. To the authors' knowledge, this is the first evidence that a drug for the treatment of FSGS supports podocyte recovery after repeated injury.Funding Information
- Mallinckrodt Pharmaceuticals (N/A)
This publication has 44 references indexed in Scilit:
- How to calculate sample size in animal studies?Journal of Pharmacology and Pharmacotherapeutics, 2013
- ForewordKidney International Supplements, 2012
- The renaissance of corticotropin therapy in proteinuric nephropathiesNature Reviews Nephrology, 2011
- Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gelDrug Design, Development and Therapy, 2011
- Melanocortin 1 Receptor Agonists Reduce ProteinuriaJournal of the American Society of Nephrology, 2010
- The basics of epithelial-mesenchymal transitionJCI Insight, 2009
- The Role of Osteopontin in the Development of AlbuminuriaJournal of the American Society of Nephrology, 2008
- Biomarkers of Acute Kidney InjuryAnnual Review of Pharmacology and Toxicology, 2008
- Melanocortin 2 receptor is required for adrenal gland development, steroidogenesis, and neonatal gluconeogenesisProceedings of the National Academy of Sciences of the United States of America, 2007
- A Randomized Pilot Trial Comparing Methylprednisolone Plus a Cytotoxic Agent Versus Synthetic Adrenocorticotropic Hormone in Idiopathic Membranous NephropathyAmerican Journal of Kidney Diseases, 2006